T S Deepak1, B N Raveesh2, B M Parashivamurthy3, Ms Narendra Kumar4, Sumanth Mallikarjuna Majgi5, H N Nagesh6. 1. Postgraduate, Department of Pharmacology, MMC&RI , Mysore, India . 2. Professor and Head, Department of Psychiatry, MMC&RI , Mysore, India . 3. Professor and Head, Department of Pharmacology, MMC&RI , Mysore, India . 4. Assistant Professor, Department of Psychiatry, MMC&RI , Mysore, India . 5. Assistant Professor, Department of Community Medicine, MMC&RI , Mysore, India . 6. Assistant Professor, Department of Pharmacology, MMC&RI , Mysore, India .
Abstract
BACKGROUND: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. OBJECTIVE: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. MATERIALS AND METHODS:Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. RESULTS: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. CONCLUSION: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.
RCT Entities:
BACKGROUND: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. OBJECTIVE: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. MATERIALS AND METHODS: Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. RESULTS: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. CONCLUSION: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.
Authors: Wesley K Kroeze; Sandra J Hufeisen; Beth A Popadak; Sean M Renock; SeAnna Steinberg; Paul Ernsberger; Karu Jayathilake; Herbert Y Meltzer; Bryan L Roth Journal: Neuropsychopharmacology Date: 2003-03 Impact factor: 7.853
Authors: Jeff J Guo; Paul E Keck; Patricia K Corey-Lisle; Hong Li; Dongming Jiang; Raymond Jang; Gilbert J L'Italien Journal: J Clin Psychiatry Date: 2006-07 Impact factor: 4.384
Authors: George N Papadimitriou; Christos G Theleritis; Dimitris G Dikeos; Constantin J Psarros; Constantin R Soldatos Journal: Int Clin Psychopharmacol Date: 2006-05 Impact factor: 1.659
Authors: Jeffrey A Lieberman; Gary Tollefson; Mauricio Tohen; Alan I Green; Raquel E Gur; Rene Kahn; Joseph McEvoy; Diana Perkins; Tonmoy Sharma; Robert Zipursky; Hank Wei; Robert M Hamer Journal: Am J Psychiatry Date: 2003-08 Impact factor: 18.112